Home > Journals > Minerva Respiratory Medicine > Past Issues > Minerva Respiratory Medicine 2023 September;62(3) > Minerva Respiratory Medicine 2023 September;62(3):114-20

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Respiratory Medicine 2023 September;62(3):114-20

DOI: 10.23736/S2784-8477.22.02029-0

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

What do we know so far about COVID-19 in sarcoidosis patients? A systematic review and meta-analysis

Amr E. EL-QUSHAYRI 1 , Abdullah DAHY 1, Ahmed M. KAMEL 2, Desouki A. ABDELATTI 3

1 Faculty of Medicine, University of Minia, Minia, Egypt; 2 Faculty of Pharmacy, University of Minia, Minia, Egypt; 3 Department for Pulmonary and Sleep Medicine, Helios University Hospital, Wuppertal, Germany



INTRODUCTION: Sarcoidosis is a systemic granulomatous disease which mainly affects the lungs in 90% of patients. In this meta-analysis, we aimed to study the symptoms, comorbidities and outcomes of sarcoidosis patients with COVID-19 infection.
EVIDENCE ACQUISITION: On 3rd November 2021 and updated in PubMed database on 7th May 2022, we searched for articles reporting COVID-19 infection in sarcoidosis patients. The analysis was done by comprehensive meta-analysis software (CMA) and the results were reported as the prevalence and 95% confidence interval (CI).
EVIDENCE SYNTHESIS: Of total 1270 patients, the most common COVID-19 symptoms were cough 70% (95% CI: 45-87), fever 56% (95% CI: 45-66) and dyspnea 40% (11-79), while the most common comorbidities were hypertension 44% (95% CI: 25-66), obesity 35% (95% CI: 10-72) and diabetes mellitus 25% (95% CI: 15-40). The prevalence of hospitalization, Intensive Care Unit (ICU) admission, patients received mechanical ventilation and mortality were 40% (95% CI: 23-61), 13% (95% CI: 5-30), 7% (95% CI: 3-17) and 8% (95% CI: 4-16), respectively.
CONCLUSIONS: Close monitoring of sarcoidosis patients with COVID-19 is essential for the prevention of the COVID-19 hazards, especially in the elderly or patients having several comorbidities. Moreover, significant prevention strategies against COVID-19 in sarcoidosis patients are recommended such as vaccination.


KEY WORDS: COVID-19; Coronavirus; Sarcoidosis; Systematic review; Meta-analysis

top of page